RxDoctor Payments Data

Tommasina Papa Rugino, MD

Neurology · Manahawkin, NJNPI 1629050554

Payments from drug & device makers

$28,818in general payments, 2019–2025

Across 1,546 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$6K
  • Biogen$3K
  • AbbVie$3K
  • EMD Serono, Inc.$2K
  • Novartis$1K
  • UCB, Inc.$1K
  • plus $13K from 48 others

What the payments were for

  • Speaking & faculty fees$5,20518%
  • Food & beverage$23,35481%
  • Education$2591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,818 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,412
Medicare patients
418
Services billed
4,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate27$253,251
Avonex Pen (4 Pack)Interferon Beta-1a12$96,627
Emgality SyringeGalcanezumab-Gnlm40$31,743
GlatopaGlatiramer Acetate12$31,688
QuliptaAtogepant23$28,981
Glatiramer Acetate14$24,681
Lamotrigine ErLamotrigine20$22,313
Aimovig AutoinjectorErenumab-Aooe23$19,385
Lacosamide47$12,553
Levetiracetam206$6,182
Memantine Hcl235$5,423
Gabapentin271$4,942
Levetiracetam ErLevetiracetam39$4,185
Teriflunomide11$4,017
Carbidopa-LevodopaCarbidopa/Levodopa188$3,754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$3,113$253,25127 claims
AbbVieQulipta$2,525$28,98123 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$468$3,26017 claims
Upsher-smith Laboratories LLCTopiramate$156$52734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Manahawkin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →